Cost-effectiveness of hepatitis A vaccination in healthcare workers

Infection Control and Hospital Epidemiology

Volumn 18, Issue 10, 1997, Pages 688-691

  Smith, Shanon ^a   Weber, Stefan ^c   Wiblin, Todd ^a   Nettleman, Mary ^b,d  

^a UNIVERSITY OF IOWA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Deutscher Akademischer A   (Germany)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS VACCINE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; CROSS INFECTION; ECONOMICS; FEMALE; HEPATITIS A; HOSPITAL PERSONNEL; HUMAN; MALE; MEDICAL STUDENT; MORTALITY; OCCUPATIONAL DISEASE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICS; UNITED STATES;

ADULT; COST-BENEFIT ANALYSIS; CROSS INFECTION; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; MALE; MARKOV CHAINS; OCCUPATIONAL DISEASES; PERSONNEL, HOSPITAL; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; STUDENTS, MEDICAL; UNITED STATES; VIRAL HEPATITIS VACCINES;

EID: 0031252816     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141508     Document Type: Article

References (31)

1. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkins; 1991:14-20.
2. US Department of Health and Human Services. Centers for Disease Control and Prevention, Hepatitis Surveillance. Report No. 55; June 1994.
3. Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 1992;10(suppl 1):S59-S61.
4. Eisenstein AB, Aach RD, Jacobsohn W, Goldman A. An epidemic of infectious hepatitis in a general hospital: probable transmission by contaminated orange juice. JAMA 1993;185:171-174.
5. Meyers JD, Romm FJ, Tihen WS, Bryan JA. Food-borne hepatitis A in a general hospital: epidemiologic study of an outbreak attributed to sandwiches. JAMA 1975;231:1049-1053.
6. Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis A among healthcare workers: risk factors for transmission. Am J Public Health 1993;83:1679-1684.
7. Germanaud J. Hepatitis A and health care personnel. Arch Intern Med 1994;154:820-822.
8. Van Damme P, Cramm M, Van der Auwera J-C, Meheus A. Hepatitis A vaccination for health care workers. BMJ 1993;306:1615.
9. Lemon SM. Inactivated hepatitis A vaccine. JAMA 1994;271:1363-1364.
10. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-1364.
11. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-457.
12. An overview of the clinical development of hepatitis A vaccine. In: Hollinger FB, ed. J Infect Dis 1995;171(suppl 1):1-77.
13. Victor J, Knudsen JD, Nielsen LP, et al. Hepatitis A vaccine: a new convenient single-dose schedule with booster when long-term immunization is warranted. Vaccine 1994;12:1327-1329.
14. Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 1994;44:443-445.
15. Van Damme P, Thoelen S, Cramm M, DeGroote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994;44:446-451.
16. Andre FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992;10(suppl):S160-S168.
17. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(suppl 1):S44-S49.
18. Wiedermann G, Ambrosch F, Andre FE, Hondt ED, Delem A, Safary A. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992;10(suppl 1):S129-S131.
19. Association of American Medical Colleges. Medical School Admission Requirements 1995-6. Washington, DC; 1994:36.
20. Steffen R, Rickenbach M, Wilhelm U, Helminger A, Schar M. Health problems after travel to developing countries. J Infect Dis 1987;156:84-91.
21. Physician Marketplace Statistics. Chicago, IL: Center for Health Policy Research. Chicago, IL: American Medical Association; 1994:24,99.
22. Centers for Disease Control and Prevention. Summary of Notifiable Diseases, United States. MMWR 1994;43(no. 53):69.
23. Tilzey AJ, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. BMJ 1991;302:1552-1553.
24. Margolis HS, Alter MJ. Will Hepatitis A become a vaccine-preventable disease? Ann Intern Med 1995;122:464-465.
25. Hawkins RE, Malone JD, Coninger LA, et al. Risk of viral hepatitis among military personnel assigned to US navy ships. J Infect Dis 1992;165:716-719.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-328.
27. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-458.
28. Van Doorslaer E, Tormans G, Van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travelers. J Med Virol 1994;44:463-469.
29. Wagner JL, Herdman RC, Wadhwa S. Cost-effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991;115:807-817.
30. Sisk JE, Riegelman RK. Cost-effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79-86.
31. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-306.